Ethyl 9-(2-benzoyloxyethyl)-8-chloro-5-methoxy-1,2,3,4-tetrahydrocarbazole-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Ethyl 9-(2-benzoyloxyethyl)-8-chloro-5-methoxy-1,2,3,4-tetrahydrocarbazole-4-carboxylate
• 英文别名: ethyl 9-(2-benzoyloxyethyl)-8-chloro-5-methoxy-1,2,3,4-tetrahydrocarbazole-4-carboxylate
• 化学式: C₂₅H₂₆ClNO₅
• 分子量: 455.9
• InChiKey: GCWHCTQATMXVNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Crystallization process of tricyclic indole derivatives
  申请人：GE Healthcare Limited

  公开号：US10709798B2

  公开（公告）日：2020-07-14

  A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent.

  一种包含三环吲哚化合物的组合物。与包含所述三环吲哚化合物的已知组合物相比，该组合物具有更高的纯度和更好的杂质分布，因此具有更优越的特性，特别是当所述化合物用于体内治疗或诊断时。
• CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES
  申请人：GE Healthcare Limited

  公开号：US20150335766A1

  公开（公告）日：2015-11-26

  A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent.
• [EN] CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES<br/>[FR] PROCÉDÉ DE CRISTALLISATION DE DÉRIVÉS D'INDOLE TRICYCLIQUES
  申请人：GE HEALTHCARE LTD

  公开号：WO2014083113A1

  公开（公告）日：2014-06-05

  The present invention relates to a composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent. Also provided by the present invention is a method to make the composition of the invention, a pharmaceutical composition comprising the composition of the invention, and use of the composition of the invention in a medical method.